Yakult to acquire Celsion's doxorubicin for Japan
This article was originally published in Scrip
Executive Summary
Yakult Honsha has signed a letter of intent to develop and commercialise in Japan Celsion's heat-activated doxorubicin product ThermoDox. The alliance remains subject to the agreement of final terms under a definitive contract.